NCT04639245 2023-08-03Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung CancerFred Hutchinson Cancer CenterPhase 1/2 Terminated1 enrolled 6 charts
NCT05775874 2023-03-20A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUCAbbisko Therapeutics Co, LtdPhase 2 Unknown80 enrolled